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aBstract
Objetives: Deficiency of 21-hydroxylase is the most common form of congenital adrenal hyperpla-
sia (CAH-21OH). The aim of this study was to determine, by allele-specific PCR, the frequency of 
microconversions of the CYP21A2, in sixteen patients with the classical forms and in 5 patients with 
the nonclassical (NC) form of CAH-21OH and correlate genotype with phenotype. Methods: Geno-
types were classified into 3 mutation groups (A, B and C), based on the degree of enzymatic activity. 
Screening for 7 microconversions by allele-specific PCR diagnosed 74.3% (n=26) of the 35 unrelated 
alleles. Results: The most frequent mutations were Q318X (25.7%), V281L (17.1%), I2 Splice (14.3%), 
I172N (14.3%), and R356W (14.3%). Genotype was identified in 57.1% of the patients. We observed 
correlation between genotype and phenotype in 91.7% of the cases. Conclusion: The highest fre-
quency for Q318X (25.7%) when compared to other studies may reflect individual sample variations 
in this Northeastern population. Arq Bras Endocrinol Metab. 2009;53(1):40-46.
Keywords
21-hydroxylase deficiency; adrenal hyperplasia; CYP21A microconversions.
resuMo
Objetivos: Deficiência de 21-hidroxilase é a forma mais comum de hiperplasia adrenal congênita 
(CAH-21OH). O objetivo deste estudo foi determinar, por PCR alelo-específica, a freqüência de 
microconversões no CYP21A2, em 16 pacientes com a forma clássica e em cinco pacientes com 
a forma não-clássica (NC) de CAH-21OH e correlacionar o genótipo com o fenótipo. Métodos: 
Genótipo foi classificado em três grupos de mutações (A, B e C), baseado no grau de atividade 
enzimática. A técnica de PCR alelo-específico diagnosticou 74,3% (n = 26) dos 35 alelos não re-
lacionados. Resultados: As mutações mais freqüentes foram Q318X (25,7%), V281L (17,1%), I2 
Splice (14,3%), I172N (14,3%) e R356W (14,3%). O genótipo foi identificado em 57,1% dos pacien-
tes. Houve correlação genótipo-fenótipo em 91,7% dos casos. Conclusão: A mais alta freqüência 
da mutação Q318X (25,7%) comparada a outros estudos pode refletir variações individuais desta 
população do nordeste. Arq Bras Endocrinol Metab. 2009;53(1):40-46.
descritores
Deficiência de 21-hidroxilase; hiperplasia adrenal; microconversões; CYP21A.
INTRODUcTION
Congenital adrenal hyperplasia (CAH) due to steroid 21-hydroxylase deficiency (CAH-21OHD) is one of 
the most common inborn endocrine disorders and is inhe-
rited in an autosomal recessive manner (1). This disease 
occurs due to molecular defects in the steroid 21-hydro-
xylase gene (CYP21A2), which encodes the 21-hydroxylase 
enzyme (2-5). The CYP21A2 gene, as well as the pseu-
dogene (CYP21A1P), is located in the HLA class III re-
gion on the short arm of chromosome 6 (6p21.3). Both 
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genes consist of 10 exons and show a high homology with 
a nucleotide identity of 98% in their exon and 96% in their 
intron sequences (6). Because of the high homology and 
tandem-repeat organization of CYP21A2, CYP21A1P, 
and C4 genes, this region of the genome is subject to une-
qual crossover events and gene conversions, which give rise 
to mutations in CYP21A2 (2-6). 
There are three major phenotypes depending on 
the degree of impairment of enzyme activity caused 
by the specific mutation in the CYP21A2 (3,4). In the 
classic salt-wasting (SW) form, the most severe form, 
patients suffer from renal salt loss due to the lack of 
aldosterone as well as pre- and postnatal virilization, due 
to accumulated adrenal androgen. Therefore, affecting 
female newborn with ambiguous external genitalia. 
In the classic simple virilizing (SV) form, patients also 
present pre- and postnatal virilization, but they do 
not have renal salt loss. In the NC form, patients lack 
the neonatal symptoms and present with late-onset 
symptoms and diagnosis (3). 
The most common source of mutations, involving 
around 95% of the alleles, is the result of recombination 
events between the homologous pseudogene (CYP21A1P) 
and the active CYP21A2 gene. In addition, more than 
100 point mutations have been described around the 
world (7). There is usually a good correlation between 
phenotype and genotype in patients with 21-hydroxylase 
deficiency (2,3,8,9). Genotypes with total or near-total 
impairment of enzymatic activity are associated with 
the SW form; the SV form is associated with severe 
impairment and the nonclassical form with moderate 
impairment of enzymatic activity. However, some 
discrepancies in genotype/phenotype correlation have 
been reported, and are associated with alternative splicing 
or the presence of additional mutations not detected in 
the screening studies. In addition, recent reports have also 
demonstrated that microconversions between CYP21A2 
and CYP21A1P promoters could be involved in the 
classical and nonclassical phenotype (10,11). 
The establishment of genotype in complete families 
with at least one CAH-21OHD-affected individual is 
useful for genetic counseling, prenatal diagnosis and 
prenatal treatment strategies, and also for differentiating 
between heterozygous and late onset form as well as 
an adjunct to hormonal measurements in screening 
programs (12,13). Therefore, in the present study, 
we report the frequency of seven CYP21A2 micro-
conversions, P30L, I2Splice, 706_713del8, I172N, 
V281L, Q318X, and R356W, using the allele-specific 
polymerase chain reaction (PCR) based approach. 
We studied 21 Brazilian families with CAH-21OH 
originating from a state in Northeast Brazil, Sergipe 
State, in order to amplify the data on the ethnic specific 
frequency of CYP21A2 gene mutations in the Brazilian 
population. In addition, we have also correlated genotype 
with phenotype in these CAH -21OHD patients.
Patients and Methods
Fifteen families and 1 isolated case with CAH-21OHD 
followed at the Division of Endocrinology, University 
Hospital of Federal University of Sergipe were studied. 
There was one affected subject in 12 families, two affec-
ted subjects in 2 families and four affected subjects in 
another family. There were no consanguineous families. 
Their parents and normal siblings were also studied. 
Among the 21 patients, 14 (66.7%) were females and 
7 (33.3%) males. Seven patients presented with the SW 
form (6 females and 1 male); 9 with the SV form (4 fe-
males and 5 males), and 5 with the NC form (4 females 
and 1 male). 
The SW form was characterized by elevated con- 
centrations of 17OHP (911.6 ± 806.5 (mean ± standard 
deviation); ranging from 32 to 1615 ng/mL), ambiguous 
genitalia in females, hyperkalemia (7.4 ± 0.8; ranging 
from 6.2 to 8.3 mEq/L), hyponatremia (125.4 ± 12.0; 
ranging from 105 to 134 mEq/L), and dehydration in 
the first months of life. The SV form was characterized 
by elevated 17OHP (151.8 ± 124.7; ranging from 10.2 
to 410.3 ng/mL), ambiguous genitalia in females, sexual 
precocity in both genders, high stature and advanced 
bone age and no history of salt wasting. The NC form was 
characterized in girls by normal external genitalia or mild 
clitoral enlargement and, in both sexes, by precocious 
pubarche and/or other signs of elevated androgens. Basal 
17OHP levels in the NC form ranged from 3.5 to 22.3 
ng/mL (13 ± 6.8 ng/mL) and 4 patients were submitted 
to exogenous ACTH (17OHP post ACTH test ranging 
from 24 to 46 ng/mL). The 17OHP cut-off value after 
the exogenous ACTH stimulation test was of 17OHP 
levels greater than 15 ng/mL. Levels of testosterone 
and androstenedione were divided by the upper limit of 
normality of the ages, to correct the different ages of the 
patients. 
Families originated from two regions in Sergipe 
State: North (5 families, 10 patients) and East (9 
families and the isolated case, 10 patients). One family 
(1 patient) originated from Bahia State. The study was 
approved by the Research Ethics Committees at the 
Federal University of Sergipe (UFS). All families gave 
their informed consent for the genetic study. 
Q318X mutation in northeast Brazil
C
o
p
yr
ig
h
t©
 A
BE
&
M
 to
d
o
s 
o
s 
d
ire
ito
s 
re
se
rv
a
d
o
s.
Arq Bras endocrinol metab. 2009;53/142
geNOTyPINg Of mUTaTIONs IN cyP21a2
DNA samples were obtained from peripheral blood 
leukocytes by standard procedures. Allele-specific PCR 
was used for the determination of 7 microconversions 
(P30L, I2Splice, 706_713del8, I172N, V281L, Q318X, 
and R356W) in 35 unrelated alleles, as previously des-
cribed (8,14). Positive and negative control DNAs were 
used in all reactions. 
geNOTyPe caTegORIes
Patients were divided into three genotype groups, ac-
cording to the impairment of enzymatic activity, as 
described by Speiser and cols. (2). Group A included 
patients who were homozygous or compound hete-
rozygous for mutations that predict 0% overall acti-
vity. Subgroup A1 included 706_713del8, Q318X, 
and R356W mutations, and Subgroup A2 included 
patients who were homozygous for I2Splice or com-
pound heterozygous for I2Splice with mutations from 
Subgroup A1. Subgroup A2 presented low, but mea-
surable, enzymatic activity (<2%). Group B included 
patients who were homozygous for I172N (2% of 
enzymatic activity) or compound heterozygous with 
mutations from Group A. Group C included patients 
who were homozygous for P30L and V281L (20-50% 
enzymatic activity) or compound heterozygous with 
mutations from Groups A or B.
sTaTIsTIcal aNalysIs
Data are expressed as mean ± standard deviation, un-
less otherwise explained. Chi-Square and Binomial 
tests were applied to compare the frequencies of the 
CYP21A2 mutated alleles observed in the present study 
and other Brazilian studies. Non-parametric tests were 
used to compare clinical and hormonal data of patients. 
The Mann-Whitney test was used to compare data be-
tween two different groups and Kruskal-Wallis test was 
used to compare data between three groups. The Pro-
gram Statistical Package for the Social Science (SPSS 
Base 8.0) was used for data analysis.
results
Table 1 shows clinical and hormonal data of patients 
with classical and NC form of CAH-21OHD, at diag-
nosis. 17OHP levels were higher in SW and SV compa-
red to NC (p=0.008 and p=0.03, respectively). Values 
of testosterone were higher in SW and SV compared to 
NC (p=0.03 and p=0.04, respectively) and in SW com-
pared to SV forms (p=0.04). Values of androstenedione 
were elevated in all forms.
table 1. Clinical and hormonal data of patients with classical 
(salt wasting: SW and simple virilizing: SV), and late onset (lo) 
forms of 21-hydroxylase deficiency, at diagnosis.
SW SV LO
Patients 7 (33.3%) 9 (42.9%) 5 (23.8%)
Age (years) 0.10 ± 0.15 2.0 ± 1.3 * 13.6 ± 10.4 *
Sex M 1 (14.3%) M 5 (55.6%) M 1 (20%)
17OHP (ng/mL) 911.6 ± 806.5 151.8 ± 124.7 † 13 ± 6.8 *
Testosterone 15 ± 10.9 5.7 ± 3.4 * † 1.5 ± 1.7 *
Androstenedione 2.6 ± 2.6 6.2 ± 4.3 1.8 ± 1.0
Sodium (mEq/L) 125.4 ± 12.0 135.3 ± 1.5 * 138 ± 1.7 *
Potassium (mEq/L) 7.4 ± 0.8 4.1 ± 0.8 * 4.6 ± 0.21 *
17OHP = 17-hidroxyprogesterone; Androstenedione = androstenedione ng/mL/upper 
limit of normality of the ages; Testosterone = testosterone/upper limit of normality of the 
ages; M: Male; * p < 0.05 in comparison to SW; † p < 0.05 SV in comparison to LO.
The distribution of the CYP21A2 mutated alleles is 
shown in Table 2, which also compares the frequencies 
observed in the present study and other Brazilian studies. 
In 35 unrelated alleles studied, the most frequent 
mutations were Q318X (25.7%), V281L (17.1%), 
I172N (14.3%), I2 Splice (14.3%), and R356W (14.3%). 
In the 12 unrelated alleles of the SW patients, 9 alleles 
(75%) were identified and the most frequent mutation 
was Q318X (58.3%), followed by R356W (16.7%), and 
I2Splice (16.7%). In the 14 alleles of the SV patients, 
10 alleles (71.4%) were identified and the most frequent 
mutation was I172N (35.7%). In the 10 alleles of the 
NC patients, 8 alleles (80%) were identified and V281L 
was the most frequent mutation (60%). 
Allele-specific PCR diagnosed 26 of the 35 
unrelated affected alleles (74.3%), 4 of them (11.4%) 
presented 2 mutations (Q318X and R356W) and 1 
allele presented 3 mutations (P30L, 706_713del8, and 
I2 Splice). When searching for the mutations in index 
case parents, we detected one asymptomatic affected 
father, who showed the V281L/I2Splice genotype, 
and had 2 affected daughters, one with SW form 
(I2Splice / Q318X, and R356W) and another with NC 
form (V281L/Q318X, and R356W). Another father 
presented homozygosity or hemizigosity for V281L, 
but his child, who presented the SW form, did not 
present identified mutations in her alleles. Paternity 
was not tested. In addition, we did not perform 
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Southern Blotting to verify the presence of deletion or 
macroconversion in father and/or child alleles. Twelve 
patients (57.1%) had their genotype identified (Table 
3); 4 presented the Group A genotype (all of them 
with the SW form), 4 patients presented the Group 
B genotype (all of them with the SV form) and 4 
patients presented the Group C genotype (3 NC and 
1 SV). There was a prevalence of 18.2 cases of CAH-
21OHD/100.000 inhabitants in the North region 
and 1.65 cases of CAH-21OHD/100.000 inhabitants 
in the East region of Sergipe State (Table 4). 
table 2. frequency of CYP21A2 microconversion in patients with classical (salt wasting: SW and simple virilizing: SV) and late onset (lo) 
forms of 21-hydroxylase deficiency.
Mutations
Present Study (2007)
Bachega and cols. (15) Torales‡ (16) Paulino and cols. (17) ‡ Torres and cols. (14) Bachega and cols. (18)
WS SV LO Total
Alleles 42 228 46 74 91 410
Q318X % 58.3 14.3 10 25.7 5.7* 13* 11.3* 1.1* 7.3*
I172N % 35.7 14.3 14 15.2 18.9 20.4 14
R356W % 16.7 14.3 20 14.3 7 6.5 8.2 6.5 11
V281L % 60 17.1 18 4.3 * 4.1 *  18.2 18
I2 sp % 16.7 21.4 14.3 20.6 21.7 24.7 14 34 *
Del8pb % 7.1 2.9 1.3 0 1.4 1.1 1.7
P30L† % 10 0 5 2.2 0 ND 1.1 1
I2Sp = I2 Splice; ND = not determined. *p<0,01. ‡, study with the classical forms. † P30L was analyzed in 20 unrelated alleles (10 LO and 10 SV).
table 3. Genotype, phenotype, and 17oH progesterone levels in patients with salt wasting (SW), simple virilizing (SV) and late onset (lo) 
forms of 21-hydroxylase deficiency.
Genotype 
(father / mother allele)
Sex
M / F
Clinical form
Age at diagnosis 
(years)
17OHP basal
(ng/mL)
17OHP 
stimulated  
(ng/mL)
Region of 
Sergipe 
Group A (subgroup A1)
Q318X / Q318X
Q318X/ Q318X
F
F
SW
SW
0.42
0.16
1600
NA
–
–
E
E
Group A (subgroup A2)
I2Splice/ Q318X
I2Splice / Q318X, R356W†
F
F
SW
SW
0.03
0.02
1615
NA
–
–
E
N
Group B
I2 Splice / I172N*
I2 Splice / I172N*
Q318X, R356W / I172N
Q318X, R356W / I172N
M
F
F
M
SV
SV
SV
SV
4.0
2.0
2.0
3.0
93.7
410.3
NA
13
–
–
–
–
N
N
N
N
Group C
V281L / V281L
V281L / Q318X, R356W†
R356W / V281L
I2 Splice / del 8pb, 
I2 Splice, P30L
F
F
F
M
LO
LO
LO (A)
SV
20.8
13.0
26.4
2.0
3.5
4.8
22.3
44.6
24.6
43.9
24.0
–
E
N
B
E
A = asymptomatic; F = female; M = male; NA = not available; E = East region of Sergipe; N = North region of Sergipe; B = Bahia; Groups A, B and C, as described by Speiser and 
cols. (2); * and †, brothers.
table 4. Prevalence of congenital adrenal hyperplasia due to 
21-hydroxylase deficiency in the North and in the east region of 
Sergipe State. 
North East 
Cases 10 10
Estimated Population 54.843 605.661 
Estimated Prevalence 18.2 / 100.000 1.65 / 100.000 *
North = Cedro de São João (5.538 inhabitants), Neópolis (20.483 inhabitants) and 
Propria (28.822 inhabitants) (19). East: Santo Amaro das Brotas (10.699 inhabitants), 
Barra dos Coqueiros (20.990 inhabitants), São Cristóvão (75.353 inhabitants) and 
Aracaju (498.619 inhabitants) (19). * p<0.0001
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discussion
In the present study, we report the frequencies of se-
ven microconversions described in CYP21A2 (P30L, 
I2Splice, 706_713del8, I172N, V281L, Q318X, and 
R356W) in a new Brazilian cohort, a population from 
Sergipe, located in the Northeast region of Brazil. The 
ethnic origin of the Brazilian population is extremely 
heterogeneous, which justifies the current study. All 
other studies on the genetic characteristics of CYP21A2 
available in the Brazilian population are restricted to the 
Southeast region of Brazil (10,11,14,15,17,18,20-26), 
especially from Sao Paulo State. We found only one 
unpublished study performed in Bahia State, which eva-
luated 30 individuals with the classical forms of CAH-
21OHD, where allele-specific PCR was used for the 
determination of 14 mutations. In 48 unrelated alleles, 
16 SW and 32 SV forms, 75% of alleles were identi-
fied. I2Splice was observed in 25%, I172N in 20% and 
Q318X in 13% of the alleles (16). 
We studied 15 families and one isolated case of CAH-
21OHD using allele-specific PCR. CYP21A2 mutation 
was detected in 74.3% of the disease-causing alleles. 
Torres and cols. (14), using the same methodology as the 
present study, identified 76% of mutated alleles. Other 
Brazilian studies, which besides screening the most 
frequent microconversions, also screened gene deletion 
and large gene conversion, identified about 80-85% 
affected alleles (15-17). Therefore, the slightly lower 
frequency of affected alleles (74.3%) observed in this study 
can be ascribed to the lack of studies on macroconversion 
and deletions, which were not evaluated systematically, 
since Southern Blotting and gene sequencing were not 
performed in the present study. 
In the present study, genotype was identified in 
57.1% of the patients, similar to other studies using the 
same diagnostic approach (14). Other studies, which 
analyzed microconversion, large gene conversion and 
deletion, genotype has been identified in up to 81% of 
the patients (15,16).
Our series presented a higher frequency for Q318X 
mutation (25.7%) compared to other worldwide studies 
(2,14-18,21,26-31). In studies from the Southeast 
region of Brazil, Q318X mutation frequency ranged 
from 1.1% (14) to 13% - 16% (16,26). The frequency 
observed in this study was even higher when compared 
to other countries, except for one study in Tunisian 
patients, in which Q318X mutation was found in 35.3% 
of the alleles (32). Kharrat and cols. (32) detected 
linkage disequilibrium between the Q318X mutation 
and a CYP21A2 gene polymorphism (601C→G at 
intron 2) in 83.3% of alleles, a loci probably due to the 
antiquity of the founder chromosomes. Moreover, the 
authors found the highest rate of consanguinity (60.8%) 
described in the literature, which probably allowed the 
dissemination of the Q318X mutation among Tunisian 
population. It is difficult to suppose the same descendant 
from Tunisian and Brazilian patients, since six out of 11 
alleles with the Q318X mutation in Sergipe´s patients 
had also the R356W mutation, which was found in 
only 2.9% of the Tunisian patients. These mutations 
(Q318X and R356W) in the same allele might have 
been transferred in a single event of gene conversion, 
since they are neighboring in pseudogene. 
Despite no recent history of consanguinity in our 
patients, the molecular study of the CYP21A2 gene 
in Bahia State also detected a higher frequency of 
Q318X mutation (13%) than the observed in previous 
Brazilian studies (16). As Bahia and Sergipe States are 
neighboring, a founder effect can be responsible for the 
high frequency of Q138X mutation in the Northeastern 
region of Brazil. Further studies in these families 
harboring the Q318X mutation, using microsatelites 
or polymorphism (SNPs) markers, will be essential 
to clarify the reason of the high frequency of Q318X 
mutation in patients with CAH-21OHD from Sergipe. 
In addition, it is important to point out that the allelic 
frequency of any CYP21A2 point mutation, including 
Q318X mutation, varies according to the number of 
patients with late onset CAH-21OHD included in the 
study. Indeed, our study as well as the Witchel and cols. 
study (26) present a small number of LO form of CAH-
21OHD and high frequency of Q318X mutation. 
The second most frequent mutation was V281L 
(17.1%). This result was similar to those obtained in 
previous Brazilian reports, where the three clinical forms 
of the CAH-21OHD were analyzed (14,15,18). On 
the other hand, V281L mutation frequency was smaller 
in series in which only classical forms of CAH-21OHD 
were studied (16,17).
I172N was present in 14.3% of unrelated alleles. This 
result is similar to those obtained in previous Brazilian 
reports (14-18). In the present study, all patients 
harboring the I172N mutation presented the SV form 
of CAH-21OHD. Some series showed discrepancy 
between genotype and phenotype associated with the 
I172N mutation, with some patients presenting the SW 
form, probably because of the low enzymatic activity 
predict by this mutation cannot be sufficient to prevent 
the salt wasting (31,33). 
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In our series the R356W mutation was found in 
14.3% of the studied alleles, similar to the frequency 
obtained in other Brazilian studies (13-17). 
I2Splice mutation was present in 14.3% of the 
studied alleles. In all Brazilian studies, it has been the 
most frequent mutation associated with the SW form 
(13-15,17,26), suggesting the diversity in Brazilian 
ethnic background. 
P30L, I2Splice, and del 8pb were found in one of 
the studied alleles. In this patient, allele–specific PCR 
could have amplified a hybrid gene, which results 
from the CYP21A2 deletion or large gene conversion, 
presenting pseudogene´s sequences in the 5´ extremity 
and sequences of the active gene in the 3´ extremity. 
Indeed, in 92% of the hybrid genes, del 8 pb is present 
(17,22). Similarly, other studies (14,22) showed patients 
harboring the del 8pb mutation in association with 
P30L and I2 Splice in the same allele, also suggesting 
a deletion or large gene conversion in CYP21A2. To 
establish the actual genotype of this patient further 
studies using Southern Blotting or gene sequencing 
should be done. 
In the present study, we found that 14.3% of the 
alleles presented more than one mutation. One 
asymptomatic affected father was diagnosed with two 
different mutations in his alleles; one of these mutations 
has been associated with severe reduction of enzymatic 
activity. He had a daughter with SW and another with 
NC form of CAH-21OHD. Indeed, it is well established 
that asymptomatic parents with different mutations in 
their alleles can generate children with different clinical 
forms of CAH-21OHD. The segregation analysis in 
this family is important to identify the genotype and 
genetic counseling. 
In one patient, we did not differentiate homozygosis 
or hemizygosity. Unfortunately, her parents were not 
available to confirm her familial segregation. In another 
patient, homozygosity was not confirmed by segregation 
analysis studies in the family, because the mutated allele 
was not identified in the father. The patient might be 
hemizygous or might have a de novo mutation. So, 
to clarify these points it will be necessary to perform 
Southern Blotting studies in these families. 
We observed a good correlation between genotype 
and phenotype. Most patients showed compound 
heterozygous mutations and the clinical form of 
CAH-21OHD was correlated with the mutated allele 
with higher enzymatic activity (3,33). Among the 
twelve patients who had mutations identified in both 
alleles, only one patient had genotype and phenotype 
discordance. This patient with the SV form of CAH-
21OHD presented I2 Splice in one allele and P30L, I2 
Splice, and del 8pb in another. In this case, I2 Splice 
can be associated with variation of phenotype, because 
a small amount of normally spliced mRNA can be 
detected and a small amount of normal enzyme can be 
synthesized (3,13,17,31,33). 
There was a higher prevalence of CAH-21OHD 
in the North region of Sergipe State. We did not find 
history of recent consanguinity among these families that 
could justify the high prevalence of cases. It is unlikely 
there was a bias in selection, since the University’s 
Hospital is the single center of reference to Sergipe 
State. Therefore, we believe that there is a higher 
number of undiagnosed patients in the other regions. 
In conclusion, our molecular analysis approach allowed 
the identification of CYP21A2 mutations in 74.3% of 
the studied alleles and identified the genotype in 57.1% 
of patients. There was a good correlation between 
genotype and phenotype. However, the frequency of 
CYP21A2 mutations in the Northeast of Brazil differed 
from other studies from Southeast of Brazil. Our dada 
amplify the knowledge on ethnic specific frequency of 
CYP21A2 mutations in the Brazilian population.
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